The problem of hypertensive heart disease regression in patients with arterial hypertension

Authors

  • S.M. Koval State Institution “L.T. Malaya National Therapy Institute of the National Academy of Medical Sciences of Ukraine”, Kharkiv, Ukraine
  • I.O. Snigurska State Institution “L.T. Malaya National Therapy Institute of the National Academy of Medical Sciences of Ukraine”, Kharkiv, Ukraine
  • V.V. Bozhko State Institution “L.T. Malaya National Therapy Institute of the National Academy of Medical Sciences of Ukraine”, Kharkiv, Ukraine
  • D.K. Miloslavsky State Institution “L.T. Malaya National Therapy Institute of the National Academy of Medical Sciences of Ukraine”, Kharkiv, Ukraine

DOI:

https://doi.org/10.22141/2224-1485.13.6.2020.223078

Keywords:

arterial hypertension, cardiovascular diseases, hypertensive heart disease, diagnostic methods, correction methods, review

Abstract

The review presents data from the domestic and foreign literature on the prevalence, pathogenesis, modern methods of verification of hypertensive heart disease (left ventricular hypertrophy) in patients with arterial hypertension and conditions associated with it: coronary heart disease, atrial fibrillation, metabolic syndrome, diabetes mellitus. Methods of non-drug and drug correction of hypertensive heart disease, as well as factors that prevent the reverse regression of hypertrophied myocardium are considered.

References

Koval SM. Problemy klasyfikatsii i diahnostyky arterialnoi hipertenzii ta stratyfikatsii ryzyku rozvytku yii uskladnen v svitli Yevropeiskykh rekomendatsii 2018 roku(komentar do rekomendatsii). Arterialna hipertenziia [Hypertension] (Ukr). 2019;1(63):3-41.

Koval SM. Diahnostyka ta likuvannia arterialnoi hipertenzii: vid rekomendatsii -do klinichnoi praktyky. Zdorovia Ukrainy [Health of Ukraine] (Ukr). 2019;(455):6.

Myloslavskyi DK, Koval SM, Snihurska IO, Starchenko TH, Bozhko VV, Yushko KA, Shcheniavska OM. Modyfikatsiia sposobu zhyttia ta diietychne kharchuvannia khvorykh na arterialnu hipertenziiu u poiednanni z tsukrovym diabetom: rekomendatsii yevropeiskykh konsensusiv ta realii zhyttia (ohliad literatury). Mizhnarodnyi endokrynolohichnyi zhurnal [International Journal of Endocrinology] (Ukr). 2018;14(2):99-110.

Sirenko YuM, Rekovets OL, Dobrokhod AS. Otsinka vplyvu mono- ta kombinovanoi antyhipertenzyvnoi terapii dyhidropirydynovymy ta nedyhidropirydynovymy antahonistamy kaltsiiu na pokaznyky ofisnoho arterialnoho tysku ta arterialnoho tysku pry dobovomu monitoruvanni u patsiientiv iz miakoiu ta pomirnoiu arterialnoiu hipertenziieiu. Arterialna hipertenziia [Hypertension] (Ukr). 2016;(1):45-66.

Sirenko Yu. N., Rekovets O. L., Kushnir S. N., Torbas E. Sravnitelnaya effektivnost enalaprila i perindoprila po vliyaniyu na tsentralnoe arterialnoe davlenie i uprugo-elasticheskie svoystva arteriy u patsientov s myagkoy i umerennoy arterialnoy gipertenziey (Rus).  Arterialna hipertenziia [Hypertension] (Ukr). 2016;(2):101-111.

Arnett DK, Devereux RB, Rao DC., et al. Novel genetic variants contributing to left ventricular hypertrophy: the HyperGEN study. J Hypertens. 2009;27(8):1585-93.

Bang CNSoliman EZSimpson LM, et al. Electrocardiographic Left Ventricular Hypertrophy Predicts Cardiovascular Morbidity and Mortality in Hypertensive Patients: The ALLHAT Study. ALLHAT Collaborative Research Group. Am J Hypertens. 2017;30(9):914-922.

Barbieri A, Bursi F, Mantovani F, et al. Left ventricular hypertrophy reclassification and death: application of the Recommendation of the American Society of Echocardiography/European Association of Echocardiography. Eur Heart J Cardiovasc Imaging. 2012;13(1):109-17.

Berezin А. Circulating biomarkers in heart failure: diagnostic and prognostic importance. Adv. Exp. Med. Biol. 2018;1067:89-108. doi: 10.1007/5584.

Bluemke DA, Kronmal RA, Lima JA, et al. The relationship of left ventricular mass and geometry to incident cardiovascular events: the MESA (Multi-Ethnic Study of Atherosclerosis) study. J Am Coll Cardiol. 2008;52(25):2148-55.

Burns J, Ball SG, Worthy G, et al. Hypertensive left ventricular hypertrophy: a mechanistic approach to optimizing regression assessed by cardiovascular magnetic resonance.J Hypertens. 2012;30(10):2039-46.

Cacciapuoti F. Molecular mechanisms of left ventricular hypertrophy (LVH) in systemic hypertension (SH)-possible therapeutic perspectives. J Am Soc Hypertens. 2011;5(6):449-55.

Codella NC, Lee HY, Fieno DS, et al. Improved left ventricular mass quantification with partial voxel interpolation: in vivo and necropsy validation of a novel cardiac MRI segmentation algorithm. Circ Cardiovasc Imaging. 2012; 5:137–46.

Cuspidi C, Facchetti R, Sala C, еt al. Normal values of left-ventricular mass: echocardiographic findings from the PAMELA study. J Hypertens. 2012;30(5):997-1003.

Cuspidi C, Facchetti R, Bombelli M, et al. Nighttime blood pressure and new-onset left ventricular hypertrophy: findings from the Pamela population. Hypertension. 2013;62(1):78-84.

Dahlöf B, Gosse JPh, Gueret P, Dubourg OJ. Perindopril/indapamide combination more effective than enalapril in reducing blood pressure and left ventricular mass: The PICXEL study. J. of Hypertension.  2005;23(11):2063-70.  doi: 10.1097/01.hjh.0000187253.35245.dc 

de Simone G, Devereux RB, Izzo R, et al. Lack of reduction of left ventricular mass in treated hypertension: the strong heart study. J Am Heart Assoc. 2013;2(3): e000144.

Devereux RB, Alonso DR, Lutas EM, et al. Echocardiographic assessment of left ventricular hypertrophy: comparison to necropsy findings. Am J Cardiology. 1986;57:450-8.

Gerdts E, Okin PM, Boman K, et al. Association of heart failure hospitalizations with combined electrocardiography and echocardiography criteria for left ventricular hypertrophy. Am J Hypertens. 2012;25(6):678-83. 

Khouri MG, Peshock RM, Ayers CR, de Lemos JA, Drazner MH. A 4-tiered сlassification of left ventricular hypertrophy based on left ventricular geometry. The Dallas Heart Study. Circ. Cardiovasc. Imaging. 2010;3:164–171.

Koval SM, Snihurska IO, Vysotska O, Strashnenko HM, Wójcik W, Dassibekov K. Prognosis of essential hypertension progression in patients with abdominal obesity. Information Technology in Medical Diagnostics II - Wójcik, Pavlov& Kalimoldayev (Eds) Taylor&Francis Group, London, 2019:275-288. doi: 10.1201/9780429057618-32.

Lang RM, Badano LP, Mor-Avi V, et al. Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American society of echocardiography and the European association of cardiovascular imaging. European Heart Journal – Cardiovascular Imaging. 2015;16: 233–271.

Lynch AI, Tang W, Shi G, et al. Epistatic effects of ACE I/D and AGT gene variants on left ventricular mass in hypertensive patients: The Hypergiant Study. Journal of human hypertension. 2012:26(2):133-40.

Macfarlane PW, Murray H, Sattar N, et al. The incidence and risk factors for new onset atrial fibrillation in the PROSPER study. Europace. 2011;13(5):634-9.

Malmqvist K, Kahan T, Isaksson H, Ostergren J. Regression of left ventricular mass with captopril and metoprolol, and the effects on glucose and lipid metabolism. Blood Press 2001;10:101–110.

Menni C, Boffi L, Cesana F, et al. Variant on chromosome 9p is associated with left ventricular mass: results from two cohorts of essential hypertensive individuals. J Hypertens. 2012;30(11):2144-50.

Mewton N, Opdahl A, Choi EY, et al. Left ventricular global function index by magnetic resonance imaging-a novel marker for assessment of cardiac performance for the prediction of cardiovascular events: the multi-ethnic study of atherosclerosis. Hypertension. 2013;61(4):770-8.

Minicucci MF, Azevedo PS, Polegato BF, et al. Cardiac remodeling induced by smoking: concepts, relevance, and potential mechanisms. Inflamm Allergy Drug Targets. 2012;11(6):442-7.

Myasoedova E, Davis JM 3rd, Crowson CS, et al. Brief report: rheumatoid arthritis is associated with left ventricular concentric remodeling: results of a population-based cross-sectional study. Arthritis Rheum. 2013;65(7):1713-8.

Okin PM, Bang CN, Wachtell K, et al. Relationship of sudden cardiac death to new-onset atrial fibrillation in hypertensive patients with left ventricular hypertrophy. Circ Arrhythm Electrophysiol. 2013;6(2):243-51.

Okin PM, Wachtell K, Devereux RB, et al. Regression of electrocardiographic left ventricular hypertrophy and decreased incidence of new-onset atrial fibrillation in patients with hypertension. JAMA. 2006;296(10):1242-8.

Panikkath R, Reinier K, Uy-Evanado A, et al. Electrocardiographic predictors of sudden cardiac death in patients with left ventricular hypertrophy. Ann Noninvasive Electrocardiol. 2013;18(3):225-9.

Radchenko G. Left ventricular hypertrophy: determination factors, methods of evaluation, possibility of regression. Ukrainian Journal of Cardiology. 2010;10(6):99-109.

Savage DD, Garrison MS, Kannel WB. et al. The spectrum of left ventricular hypertrophy in a general population sample: The Framingham Study. Circulation. 1987;75 1 (Pt 2): I-26–I-33.

Schiller NB, Shah P, Crawford M, et al. Recommendations for quantitation of the left ventricle by two-dimensional echocardiography. American Society of Echocardiography committee on standards, subcommittee on quantitation of two-dimensional echocardiograms. J. Am Soc Echocardiography. 1989;2:358-67.

Soliman EZ, Byington RP, Bigger JT, et al. Effect of Intensive Blood Pressure Lowering on Left Ventricular Hypertrophy in Patients With Diabetes Mellitus: Action to Control Cardiovascular Risk in Diabetes Blood Pressure Trial. Hypertension. 2015;66(6):1123-9.

Thomopoulos CParati GZanchetti A. Effects of blood pressure lowering on outcome incidence in hypertension: Effects of more vs. less intensive blood pressure lowering and different achieved blood pressure levels - updated overview and meta-analyses of randomized trials. J Hypertens. 2016;34(4):613-22.

Troy B, Pombo J, Rackley CE. Measurement of left ventricular wall thickness and mass by echocardiography. Circulation.1972;45:602-11.

Verdecchia P, Angeli F, Gattobigio R, еt al. Regression of left ventricular hypertrophy and prevention of stroke in hypertensive subjects. J Hypertens. 2006;19(5):493-9.

Verma A, Meris A, Skali H, et al. Prognostic implications of left ventricular mass and geometry following myocardial infarction: the VALIANT (VALsartan In Acute myocardial iNfarcTion) Echocardiographic Study. JACC Cardiovasc Imaging. 2008;1(5):582-91.

Williams B, Mancia G, Spiering W, et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension. European Heart Journal. 2018;39 (Issue 33):3021–3104.

Published

2020-11-01

Issue

Section

Review